Inventiva S.A. (NASDAQ:IVA) presented at its Analyst/Investor Day, emphasizing lanifibranor as a potential best-in-category oral therapy for MASH. Chairman Mark Pruzanski highlighted a successful year, marked by a $400-plus million PIPE financing completed approximately a year prior and the accelerated, over-enrollment of its global Phase III NATiV3 trial, which was announced in April. These milestones position Inventiva's lead MASH candidate for continued development.
Inventiva S.A. (NASDAQ:IVA) Analyst/Investor Day October 8, 2025 11:30 AM EDT Company Participants Mark Pruzanski Andrew Obenshain - CEO & Director Jason Campagna - President of Research and Development & Chief Medical Officer Martine Zimmermann - Executive VP of Regulatory Affairs & Quality Assurance Conference Call Participants William Alazawi Arun Sanyal Nezam H. Afdhal Henry E. Chang Seamus Fernandez - Guggenheim Securities, LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Ritu Baral - TD Cowen, Research Division Edward Nash - Canaccord Genuity Corp., Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Antonio Arce - WestPark Capital, Inc., Research Division Presentation Mark Pruzanski Okay. Why don't we kick things off. Hi, everyone. I'm Mark Pruzanski, I'm the Chairman of the Board of Inventiva and welcome to our investor event. We're going to be telling you today about the next and hopefully best-in-category oral therapy to get to patients with MASH, lanifibranor. We're going to be making forward-looking statements. Here's the agenda. It's going to be pretty packed, and I'm going to get out of your way and introduce you to Andrew in a minute followed by 3 well-known, key opinion-leading hepatologists in the MASH space. And then we will a panel discussion with some of the senior management team and time for Q&A at the end. So I've been involved with Inventiva for the better part of the year. And it's been a momentous year. All of you know that we just about a year ago raised a $400-plus million pipe, which positioned the company very well with respect to the enrollment of the global Phase III NATiV3 trial. We double-clicked to accelerate enrollment and over enrolled the study, which we announced in April of this year. And then Inventiva S.A. (NASDAQ:IVA) hosted an Analyst/Investor Day, emphasizing lanifibranor as a potential "best-in-category oral therapy" for Metabolic Dysfunction-Associated Steatohepatitis (MASH). Chairman Mark Pruzanski highlighted the company's strategic focus on addressing this significant unmet medical need through their lead candidate. This event underscores Inventiva's commitment to advancing its pipeline and communicating key milestones to the investment community. A pivotal financial achievement noted was the successful $400-plus million PIPE financing, completed approximately one year prior, which substantially strengthened the company's capital structure. This funding was critical for the execution of the global Phase III NATiV3 trial. Operational efficiency was demonstrated by the accelerated and over-enrollment of this study, an update announced in April. The overall sentiment surrounding Inventiva is characterized as "strongly positive" with an "optimistic" tone, reflecting these significant operational and financial advancements. These developments position IVA favorably within the competitive MASH treatment landscape, signaling robust progress and potential for future value creation as clinical data unfolds.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
